Cytomegalovirus infection and disease following renal transplantation: preliminary report of incidence and potential risk factors.

[1]  C. Drachenberg,et al.  Thymoglobulin Dose Optimization for Induction Therapy in High Risk Kidney Transplant Recipients , 2008, Transplantation.

[2]  A. Mehrsai,et al.  Infectious complications after kidney transplantation: a single‐center experience , 2007, Transplant infectious disease : an official journal of the Transplantation Society.

[3]  H. Khedmat,et al.  Cytomegalovirus disease after kidney transplantation: clues to accurate diagnosis. , 2007, Transplantation proceedings.

[4]  P. Khashayar,et al.  Clinical manifestation, laboratory findings, and the response of treatment in kidney transplant recipients with CMV infection. , 2007, Transplantation proceedings.

[5]  J. Ringers,et al.  Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. , 2006, Diabetes care.

[6]  H. Rollag,et al.  Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. , 2004, Kidney international.

[7]  M. Schnitzler.  Costs and consequences of cytomegalovirus disease. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[8]  J. Briggs,et al.  Management of cytomegalovirus infection by weekly surveillance after renal transplant: analysis of cost, rejection and renal function. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  Luc Perrin,et al.  Monitoring of Cytomegalovirus Infection in Solid-Organ Transplant Recipients by an Ultrasensitive Plasma PCR Assay , 2003, Journal of Clinical Microbiology.

[10]  Fatema Jawad,et al.  Renal transplantation in developing countries. , 2003, Kidney international. Supplement.

[11]  R. Poropatich,et al.  Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. , 2002, Annals of epidemiology.

[12]  P. Griffiths,et al.  Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  D. Brennan.  Cytomegalovirus in renal transplantation. , 2001, Journal of the American Society of Nephrology : JASN.

[14]  T. Chan,et al.  Association between anti-thymocyte globulin administration and cytomegalic virus infection and/or CMV disease in cadaveric renal allograft recipients. , 2000, Transplantation proceedings.

[15]  D. Brennan,et al.  Effects of storage temperature and time on qualitative and quantitative detection of cytomegalovirus in blood specimens by shell vial culture and PCR , 1997, Journal of clinical microbiology.

[16]  C. Payá,et al.  Infections in solid-organ transplant recipients , 1997, Clinical microbiology reviews.

[17]  T. Howard,et al.  Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. , 1997, Journal of the American Society of Nephrology : JASN.

[18]  T. Mohanakumar,et al.  Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial. , 1994, Transplantation.

[19]  R. Écochard,et al.  Cytomegalovirus infection--an etiological factor for rejection? A prospective study in 242 renal transplant patients. , 1993, Transplantation.

[20]  F. Veith,et al.  Timing of cyclosporine administration in patients with delayed graft function. , 1987, The Journal of surgical research.

[21]  R. Filo,et al.  Reversal of acute renal allograft rejection with adjunctive AG therapy. , 1981, Transplantation Proceedings.